Cargando…
The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations
Pulmonary arterial hypertension (PAH) is characterized by dysregulated pulmonary artery endothelial cell (PAEC) proliferation, apoptosis and permeability. Loss-of-function mutations in the bone morphogenetic protein receptor type-II (BMPR-II) are the most common cause of heritable PAH, usually resul...
Autores principales: | Dunmore, Benjamin J., Drake, Kylie M., Upton, Paul D., Toshner, Mark R., Aldred, Micheala A., Morrell, Nicholas W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749859/ https://www.ncbi.nlm.nih.gov/pubmed/23669347 http://dx.doi.org/10.1093/hmg/ddt216 |
Ejemplares similares
-
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
por: Long, Lu, et al.
Publicado: (2015) -
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension
por: Ormiston, Mark L., et al.
Publicado: (2015) -
Hematopoietic stem cell transplantation alters susceptibility to pulmonary hypertension in Bmpr2-deficient mice
por: Crosby, Alexi, et al.
Publicado: (2018) -
Targeting translational read-through of premature termination
mutations in BMPR2 with PTC124 for pulmonary arterial
hypertension
por: Long, Lu, et al.
Publicado: (2020) -
BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas
por: O’Neill, Hannah L., et al.
Publicado: (2016)